290 related articles for article (PubMed ID: 11960915)
1. Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy.
Stiborová M; Frei E; Sopko B; Wiessler M; Schmeiser HH
Carcinogenesis; 2002 Apr; 23(4):617-25. PubMed ID: 11960915
[TBL] [Abstract][Full Text] [Related]
2. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase.
Stiborová M; Frei E; Sopko B; Sopková K; Marková V; Lanková M; Kumstýrová T; Wiessler M; Schmeiser HH
Carcinogenesis; 2003 Oct; 24(10):1695-703. PubMed ID: 12869422
[TBL] [Abstract][Full Text] [Related]
3. Carcinogenic and nephrotoxic alkaloids aristolochic acids upon activation by NADPH : cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy.
Stiborová M; Hájek M; Frei E; Schmeiser HH
Gen Physiol Biophys; 2001 Dec; 20(4):375-92. PubMed ID: 11989648
[TBL] [Abstract][Full Text] [Related]
4. Evidence for reductive activation of carcinogenic aristolochic acids by prostaglandin H synthase -- (32)P-postlabeling analysis of DNA adduct formation.
Stiborová M; Frei E; Breuer A; Wiessler M; Schmeiser HH
Mutat Res; 2001 Jun; 493(1-2):149-60. PubMed ID: 11516724
[TBL] [Abstract][Full Text] [Related]
5. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy.
Bieler CA; Stiborova M; Wiessler M; Cosyns JP; van Ypersele de Strihou C; Schmeiser HH
Carcinogenesis; 1997 May; 18(5):1063-7. PubMed ID: 9163697
[TBL] [Abstract][Full Text] [Related]
6. Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy.
Stiborová M; Frei E; Breuer A; Bieler CA; Schmeiser HH
Exp Toxicol Pathol; 1999 Jul; 51(4-5):421-7. PubMed ID: 10445409
[TBL] [Abstract][Full Text] [Related]
7. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer.
Stiborová M; Frei E; Hodek P; Wiessler M; Schmeiser HH
Int J Cancer; 2005 Jan; 113(2):189-97. PubMed ID: 15386410
[TBL] [Abstract][Full Text] [Related]
8. Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2.
Stiborová M; Frei E; Wiessler M; Schmeiser HH
Chem Res Toxicol; 2001 Aug; 14(8):1128-37. PubMed ID: 11511187
[TBL] [Abstract][Full Text] [Related]
9. Characterization of DNA adducts formed by aristolochic acids in the target organ (forestomach) of rats by 32P-postlabelling analysis using different chromatographic procedures.
Stiborová M; Fernando RC; Schmeiser HH; Frei E; Pfau W; Wiessler M
Carcinogenesis; 1994 Jun; 15(6):1187-92. PubMed ID: 8020154
[TBL] [Abstract][Full Text] [Related]
10. Comparison of DNA adduct formation by aristolochic acids in various in vitro activation systems by 32P-post-labelling: evidence for reductive activation by peroxidases.
Schmeiser HH; Frei E; Wiessler M; Stiborova M
Carcinogenesis; 1997 May; 18(5):1055-62. PubMed ID: 9163696
[TBL] [Abstract][Full Text] [Related]
11. Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases.
Martinek V; Kubickova B; Arlt VM; Frei E; Schmeiser HH; Hudecek J; Stiborova M
Neuro Endocrinol Lett; 2011; 32 Suppl 1():57-70. PubMed ID: 22167209
[TBL] [Abstract][Full Text] [Related]
12. Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy.
Stiborová M; Frei E; Arlt VM; Schmeiser HH
Mutat Res; 2008; 658(1-2):55-67. PubMed ID: 17851120
[TBL] [Abstract][Full Text] [Related]
13. Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: evidence of their contribution to aristolochic acid I detoxication and activation in rat liver.
Stiborova M; Mares J; Levova K; Pavlickova J; Barta F; Hodek P; Frei E; Schmeiser HH
Neuro Endocrinol Lett; 2011; 32 Suppl 1():121-30. PubMed ID: 22167220
[TBL] [Abstract][Full Text] [Related]
14. The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen.
Stiborová M; Sopko B; Hodek P; Frei E; Schmeiser HH; Hudecek J
Cancer Lett; 2005 Nov; 229(2):193-204. PubMed ID: 16125300
[TBL] [Abstract][Full Text] [Related]
15. 32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II.
Pfau W; Schmeiser HH; Wiessler M
Carcinogenesis; 1990 Sep; 11(9):1627-33. PubMed ID: 2401053
[TBL] [Abstract][Full Text] [Related]
16. Detection and quantitation of dG-AAI and dA-AAI adducts by 32P-postlabeling methods in urothelium and exfoliated cells in urine of rats treated with aristolochic acid I.
Fernando RC; Schmeiser HH; Nicklas W; Wiessler M
Carcinogenesis; 1992 Oct; 13(10):1835-9. PubMed ID: 1423842
[TBL] [Abstract][Full Text] [Related]
17. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review.
Arlt VM; Stiborova M; Schmeiser HH
Mutagenesis; 2002 Jul; 17(4):265-77. PubMed ID: 12110620
[TBL] [Abstract][Full Text] [Related]
18. The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers.
Stiborova M; Frei E; Arlt VM; Schmeiser HH
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):5-11. PubMed ID: 19365519
[TBL] [Abstract][Full Text] [Related]
19. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy.
Schmeiser HH; Bieler CA; Wiessler M; van Ypersele de Strihou C; Cosyns JP
Cancer Res; 1996 May; 56(9):2025-8. PubMed ID: 8616845
[TBL] [Abstract][Full Text] [Related]
20. Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/polyacrylamide gel electrophoresis analysis.
Dong H; Suzuki N; Torres MC; Bonala RR; Johnson F; Grollman AP; Shibutani S
Drug Metab Dispos; 2006 Jul; 34(7):1122-7. PubMed ID: 16611860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
